NASDAQ:RVPH Reviva Pharmaceuticals (RVPH) Stock Price, News & Analysis $0.44 -0.03 (-6.90%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$0.44 +0.00 (+0.78%) As of 08/1/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Reviva Pharmaceuticals Stock (NASDAQ:RVPH) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Reviva Pharmaceuticals alerts:Sign Up Key Stats Today's Range$0.42▼$0.4650-Day Range$0.34▼$1.1252-Week Range$0.30▼$4.28Volume1.75 million shsAverage Volume2.97 million shsMarket Capitalization$20.91 millionP/E RatioN/ADividend YieldN/APrice Target$9.00Consensus RatingBuy Company Overview Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California. Read More Reviva Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks57th Percentile Overall ScoreRVPH MarketRank™: Reviva Pharmaceuticals scored higher than 57% of companies evaluated by MarketBeat, and ranked 477th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingReviva Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.29, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageReviva Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Reviva Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Reviva Pharmaceuticals are expected to grow in the coming year, from ($0.97) to ($0.79) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Reviva Pharmaceuticals is -0.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Reviva Pharmaceuticals is -0.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioReviva Pharmaceuticals has a P/B Ratio of 21.78. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Reviva Pharmaceuticals' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.60% of the outstanding shares of Reviva Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverReviva Pharmaceuticals has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Reviva Pharmaceuticals has recently increased by 68.99%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldReviva Pharmaceuticals does not currently pay a dividend.Dividend GrowthReviva Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted12.60% of the outstanding shares of Reviva Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverReviva Pharmaceuticals has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Reviva Pharmaceuticals has recently increased by 68.99%, indicating that investor sentiment is decreasing significantly. News and Social Media1.9 / 5News Sentiment-0.50 News SentimentReviva Pharmaceuticals has a news sentiment score of -0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Reviva Pharmaceuticals this week, compared to 1 article on an average week.Search Interest32 people have searched for RVPH on MarketBeat in the last 30 days. This is an increase of 256% compared to the previous 30 days.MarketBeat Follows10 people have added Reviva Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Reviva Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders27.18% of the stock of Reviva Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions63.18% of the stock of Reviva Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Reviva Pharmaceuticals' insider trading history. Receive RVPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Reviva Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address RVPH Stock News HeadlinesReviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Receives Consensus Recommendation of "Buy" from AnalystsJuly 30 at 2:31 AM | americanbankingnews.comReviva Pharmaceuticals Holdings, Inc. (RVPHW) - Yahoo FinanceJuly 5, 2025 | finance.yahoo.comIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as October 23rd.August 2 at 2:00 AM | Brownstone Research (Ad)Reviva Pharmaceuticals Holdings, Inc. (RVPH) - Investing.comJune 29, 2025 | investing.comReviva Dives on Stock OfferingJune 26, 2025 | baystreet.caReviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public OfferingJune 26, 2025 | globenewswire.comReviva Pharmaceuticals stock falls after announcing public offeringJune 25, 2025 | za.investing.comReviva Pharmaceuticals Holdings, Inc. Announces Proposed Public OfferingJune 25, 2025 | globenewswire.comSee More Headlines RVPH Stock Analysis - Frequently Asked Questions How have RVPH shares performed this year? Reviva Pharmaceuticals' stock was trading at $1.81 at the beginning of the year. Since then, RVPH stock has decreased by 75.9% and is now trading at $0.4356. How were Reviva Pharmaceuticals' earnings last quarter? Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) posted its quarterly earnings results on Thursday, May, 15th. The company reported ($0.13) earnings per share for the quarter, beating analysts' consensus estimates of ($0.21) by $0.08. How do I buy shares of Reviva Pharmaceuticals? Shares of RVPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Reviva Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Reviva Pharmaceuticals investors own include Sangamo Therapeutics (SGMO), Salesforce (CRM), Adobe (ADBE), Advanced Micro Devices (AMD), CrowdStrike (CRWD), Airbnb (ABNB) and Marvell Technology (MRVL). Company Calendar Last Earnings5/15/2025Today8/02/2025Next Earnings (Estimated)8/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:RVPH CIK1742927 Webwww.revivapharma.com Phone(408) 501-8881FaxN/AEmployees5Year FoundedN/APrice Target and Rating Average Price Target for Reviva Pharmaceuticals$9.00 High Price Target$17.00 Low Price Target$3.00 Potential Upside/Downside+1,966.1%Consensus RatingBuy Rating Score (0-4)3.29 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($0.79) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$29.92 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-302.31% Debt Debt-to-Equity RatioN/A Current Ratio0.54 Quick Ratio0.54 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.02 per share Price / Book21.78Miscellaneous Outstanding Shares48,000,000Free Float34,957,000Market Cap$20.91 million OptionableOptionable Beta-0.05 Social Links 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:RVPH) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersWhy Elon put $51 million into thisA single U.S. company has started producing a “miracle metal” once locked in research labs. Now? They’re qu...True Market Insiders | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | SponsoredTrump’s crypto advisor may have revealed the next big crypto opportunityWhile investors chase Bitcoin toward $100K, D.C. insiders are quietly loading up on something else. One of Tru...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Reviva Pharmaceuticals Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Reviva Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.